{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:25:01Z","timestamp":1755224701373,"version":"3.43.0"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Alcohol use among patients in treatment for illicit substance use disorder (SUD) is often overlooked, at best perceived as a secondary issue, despite growing evidence of exacerbated negative health outcomes among polysubstance users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We analyse a nationwide dataset on patients entering treatment for cannabis, opioid, and stimulant use disorders in France between 2012 and 2022. We conduct multilevel logistic regressions to determine the main predictors of problematic alcohol use (PAU) among patients who entered treatment for cannabis (<jats:italic>n<\/jats:italic>\u2009=\u2009308,906), opioid (<jats:italic>n<\/jats:italic>\u2009=\u2009255,879) or stimulant (<jats:italic>n<\/jats:italic>\u2009=\u200960,211) use disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PAU remains a common behaviour among patients with SUD (overall prevalence: 28.2%, 95% confidence interval [CI] 28.1\u201328.3), with lower prevalence among patients treated for cannabis (27.3%, 95% CI 27.2\u201327.5) and opioid disorders (27.2%, 95% CI 27.0\u201327.4), and higher for patients treated for stimulant disorders (36.8%, 95% CI 36.4\u201337.2). There is an increase in PAU over time for each of the SUD leading to treatment (23.0% in 2012 vs. 29.5% in 2022; 23.3% vs. 31.4% and 29.7% vs. 38.9% respectively). Males, older people, early onset, current use of tobacco, and psychiatric comorbidities are positively associated with PAU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>The increasing prevalence of problematic alcohol use among patients treated for SUD in France remains a source of concern. Screening for both alcohol and drug use among patients in treatment presents a crucial opportunity to prevent and treat SUDs early, especially among patients treated for stimulants.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.14078","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:36:48Z","timestamp":1747636608000},"page":"1513-1521","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Prevalence and Correlates of Problematic Alcohol Use Among Patients Treated for Illicit Substance Disorder in France, 2012\u20132022"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-9657","authenticated-orcid":false,"given":"Eric","family":"Janssen","sequence":"first","affiliation":[{"name":"Observatoire Fran\u00e7ais Des Drogues et Des Tendances Addictives  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Vuolo","sequence":"additional","affiliation":[{"name":"Department of Sociology Ohio State University  Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"V\u00e9ron","sequence":"additional","affiliation":[{"name":"Observatoire Fran\u00e7ais Des Drogues et Des Tendances Addictives  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivette Flores","family":"Laffont","sequence":"additional","affiliation":[{"name":"Universidad de Guadalajara Centro Universitario de Tonal\u00e1  Tonal\u00e1 M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"volume-title":"Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders","year":"2024","author":"World Health Organization","key":"e_1_2_11_2_1"},{"key":"e_1_2_11_3_1","first-page":"278","article-title":"Estimation of Deaths Attributable to Tobacco Smoking, in France From 2000 to 2015","volume":"15","author":"Bonaldi C.","year":"2019","journal-title":"Behaviour"},{"volume-title":"Le Co\u00fbt Social Des Drogues: Estimation en France en 2019 [the Social Cost of Drugs: An Estimation in France in 2019]","year":"2023","author":"Kopp P.","key":"e_1_2_11_4_1"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.11.059"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114741"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19706"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01630.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.05.035"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.008"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.03.006"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.602995"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108886"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2012.12.001"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-10-42"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.3788"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.11.010"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03675.x"},{"volume-title":"Guidelines for Estimating the Incidence of Problem Drug Use","year":"2004","author":"EMCDDA","key":"e_1_2_11_20_1"},{"volume-title":"PDU (Problem Drug Use) Revision Summary","year":"2023","author":"EMCDDA","key":"e_1_2_11_21_1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-2719-6_6"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2004.023929"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000363232"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2018.79.799"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.08.021"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.09.009"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.09.007"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0741-8329(85)90081-3"},{"issue":"11","key":"e_1_2_11_30_1","first-page":"833","article-title":"Alcohol Enquiry by GPs \u2010 Understanding Patients' Perspectives: A Qualitative Study","volume":"44","author":"Tam C. W.","year":"2015","journal-title":"Australian Family Physician"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/16066359.2020.1820491"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01592.x"},{"volume-title":"Health Literacy: A Prescription to End Confusion","year":"2004","author":"Institute of Medicine Committee on Health Literacy","key":"e_1_2_11_33_1"},{"volume-title":"High Drug Availability Fuelled by Large\u2010Volume Imports and Production Within the European Union","year":"2024","author":"EUDA","key":"e_1_2_11_34_1"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1441.030"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100153"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00426-5"},{"key":"e_1_2_11_38_1","first-page":"1","article-title":"Les Niveaux D'usage Des Drogues Illicites En France En 2023 [Levels of Illicit Substance Use in France in 2023]","volume":"164","author":"Spilka S.","year":"2024","journal-title":"Tendances"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/08897077231191005"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.14078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T01:24:40Z","timestamp":1755048280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.14078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/dar.14078"],"URL":"https:\/\/doi.org\/10.1111\/dar.14078","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"type":"print","value":"0959-5236"},{"type":"electronic","value":"1465-3362"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"2025-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}